UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13E-3
(AMENDMENT
NO. 1)
RULE
13e-3 TRANSACTION STATEMENT
(Pursuant
to Section 13(e) of the Securities Exchange Act of 1934)
TONGJITANG
CHINESE MEDICINES COMPANY
(Name of
Issuer)
TONGJITANG
CHINESE MEDICINES COMPANY
HANMAX
INVESTMENT LIMITED
FOSUN
INDUSTRIAL CO., LIMITED
TONSUN
INTERNATIONAL COMPANY LIMITED
M
R. XIAOCHUN
WANG
S
HANGHAI FOSUN
PHARMACEUTICAL (GROUP) CO. LTD
.
FOSUN HIGH TECHNOLOGY (GROUP) CO. LTD
.
F
OSUN
INTERNATIONAL LIMITED
FOSUN HOLDINGS LIMITE
D
F
OSUN
INTERNATIONAL HOLDINGS LTD.
MR. GUANGCHANG GU
O
(Names of
Persons Filing Statement)
ORDINARY
SHARES
(Title of
Class of Securities)
G8918E106
(CUSIP
Number)
Mr. Justin Chen
|
|
Mr. Xiaochun Wang
|
|
Mr. Jianguo Yang
|
Tongjitang Chinese Medicines
Company
|
|
Room 3030, Four Seasons Place
8 Finance Street, Central
|
|
Fosun Industrial Co.,
Limited
|
5
th
Floor, Block B, Nanshan Medical
Device Park
|
|
|
|
Level 28, Three Pacific
Place
|
1019 Nanhai Avenue, Shekou,
Nanshan District
|
|
|
|
1 Queen’s Road East
|
Shenzhen, 518067 Guangdong
Province
|
|
|
|
(8621) 6332 5563
|
People’s Republic of China
|
|
|
|
|
(86755) 2667
0969
|
|
|
|
|
(Name,
Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
With
copies to:
|
|
|
|
|
Jason
Schendel, Esq.
|
|
Yi
Zhu, Esq.
|
Suite
3401, China World Tower 2
|
Sheppard
Mullin Richter & Hampton LLP
|
|
26/F
Wheelock Square
|
1
Jianguomenwai Dajie, Beijing 100004
|
1717
Nanjing Road West, Shanghai 200040
|
|
China
|
telephone:
(8610) 6535 3971
|
telephone
: (8621) 2321
6000
|
email:
scott.clemens@bakermckenzie.com
|
|
|
390
Lytton Avenue,
|
|
Palo
Alto, California 94301
|
|
U.S.A
|
|
telephone:
(650) 815 2640
|
|
fax:
(650) 815-4653
|
|
email:
llehot@sheppardmullin.com
|
|
This
statement is filed in connection with (check the appropriate box):
a.
|
o
|
The
filing of solicitation materials or an information statement subject to
Regulation 14A, Regulation 14-C or Rule 13e-3(c) under the
Securities Exchange Act of 1934.
|
b.
|
o
|
The
filing of a registration statement under the Securities Act of
1933.
|
Check the
following box if the soliciting materials or information statement referred to
in checking box (a) are preliminary copies:
þ
Check the
following box if the filing is a final amendment reporting the results of the
transaction:
o
Calculation of Filing
Fee
Transactional
Valuation*
|
|
|
Amount
of Filing Fee**
|
|
$
|
20,235,993.75
|
|
|
$
|
1,442.83
|
|
*
|
Calculated
solely for the purpose of determining the filing fee in accordance with
Rule 0-11(b)(1) under the Securities Exchange Act of 1934, as amended. The
filing fee is calculated based on the aggregate cash payment for the
proposed per share cash payment of $1.125 for 17,987,550 outstanding
ordinary shares of the issuer subject to the
transaction.
|
**
|
The
amount of the filing fee, calculated in accordance with Exchange Act
Rule 0-11(b)(1) was calculated by multiplying the transaction value
by 0.0000713.
|
þ
|
Check
box if any part of the fee is offset as provided by Rule 0-11(a)(2)
and identify the filing with which the offsetting of the fee was
previously paid. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its
filing.
|
Amount
Previously Paid: $1,442.83
Form or
Registration No.: Schedule 13e-3
Filing
Party: Tongjitang Chinese Medicines Company
Date
Filed: November 26, 2010
TABLE OF CONTENTS
|
Page
|
INTRODUCTION
|
3
|
|
|
Item 1.
Summary of Term Sheet
|
4
|
Item 2.
Subject Company Information
|
4
|
Item 3.
Identity and Background of Filing Person
|
4
|
Item 4.
Terms of the Transaction
|
4
|
Item 5.
Past Contacts, Transactions, Negotiations and Agreements
|
5
|
Item 6.
Purposes of the Transaction and Plans or Proposals
|
6
|
Item 7.
Purposes, Alternatives, Reasons and Effects
|
6
|
Item 8.
Fairness of the Transaction
|
7
|
Item 9.
Reports, Opinions, Appraisals and Negotiations
|
7
|
Item 10.
Source and Amounts of Funds or Other Consideration
|
8
|
Item 11.
Interest in Securities of the Subject Company
|
8
|
Item 12.
The Solicitation or Recommendation
|
9
|
Item 13.
Financial Statements
|
9
|
Item 14.
Persons/Assets, Retained, Employed, Compensated or Used
|
9
|
Item 15.
Additional Information
|
9
|
Item 16.
Exhibits
|
9
|
INTRODUCTION
This
Amendment No.1 amends the Rule 13e-3 Transaction Statement on Schedule
13E-3, together with the exhibits hereto ( as amended, the “Transaction
Statement”), and is being filed with the Securities and Exchange
Commission (“SEC”) by (a) Tongjitang Chinese Medicines Company, a Cayman Islands
company (“Tongjitang”), the issuer of the ordinary shares, par value $0.001 per
share (individually a “Share” and collectively the “Shares”), that is subject to
the transaction pursuant to Rule 13e-3 under the Securities Exchange Act of
1934, as amended (the “Exchange Act”), (b) Hanmax Investment Limited, a British
Virgin Islands company (“Hanmax”) (c), Fosun Industrial Co., Limited,
(“Fosun”), a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)
Co. Ltd. (“Fosun Pharma”), (d) Tonsun International Company
Limited, a Cayman Islands company (“Merger Sub”)
, (e)
Mr. Xiaochun Wang, chairman of the board and chief executive officer of
Tongjitang and the sole shareholder, officer and director of Hanmax, (f) Fosun
Pharma, a subsidiary of Shanghai Fosun High Technology (Group) Co. Ltd. (“Fosun
High Technology”), (g) Fosun High Technology, a wholly owned subsidiary of Fosun
International Limited (“Fosun International”), (h) Fosun International, a
subsidiary of Fosun Holdings Limited (“Fosun Holdings”), (i) Fosun Holdings, a
wholly owned subsidiary of Fosun International Holdings Ltd. (“Fosun
International Holdings”) and (j) Mr. Guangchang Guo, who controls Fosun
International Holdings and could therefore be deemed the beneficial owner of the
Shares held by Fosun Industrial. The above filing persons, collectively, are
referred to herein as the “Filing Persons”, and the Filing Persons other
than Tongjitang are sometimes referred to herein as the “Buyer Parties.”
However, in the Merger Agreement and where the terms of the Merger Agreement are
described, the term
“Buyer Parties
” refers to Hanmax, Fosun
and Merger Sub only.
This
Transaction Statement relates to the agreement and plan of merger dated as of
October 29, 2010 (the “Merger Agreement”), among Tongjitang, Hanmax, Fosun and
Merger Sub. If the Merger Agreement is adopted by Tongjitang’s shareholders and
the other conditions to the closing of the Merger (as such term is defined
below) are satisfied or waived, Merger Sub will merge with and into Tongjitang
with Tongjitang continuing as the surviving corporation (the
“Merger”).
If the
Merger is completed, each Share and American Depositary Share, each of which
represents four Shares (“ADSs”), issued and outstanding immediately prior to the
effectiveness of the Merger (other than the Shares and ADSs owned by Hanmax and
Fosun and their subsidiaries and Shares held by holders who have validly
exercised and have not effectively withdrawn or lost their appraisal rights
under Cayman Islands law, which are referred to herein as company
dissenting shares) will be cancelled in exchange for the right to receive $1.125
in cash per Share ($4.50 per ADS), in each case without interest and less any
applicable taxes. In addition, each outstanding option to
purchase the Shares under Tongjitang’s share incentive plan, vested
or unvested, will be cancelled and converted into the right to receive, as soon
as reasonably practicable after the effective time of the Merger, a cash payment
equal to the number of Shares underlying such option multiplied by the amount by
which $1.125 exceeds the exercise price per share of such option. Because
none of the outstanding options have an exercise price greater than
$1.125 per share , option holders will not be eligible to receive any
consideration in the Merger . The Merger remains subject to the
satisfaction or waiver of the conditions set forth in the Merger Agreement,
including obtaining the requisite approval of the shareholders of
Tongjitang.
Tongjitang
will make available to its shareholders a proxy statement (the “Proxy
Statement,” a copy of which is attached as Exhibit (a)(1) to this Transaction
Statement), relating to the extraordinary general meeting of shareholders of
Tongjitang, at which the shareholders will consider and vote upon, among other
proposals, a proposal to approve the Merger and approve and adopt the
Merger Agreement and the other transactions contemplated thereby. As
of the date hereof, the Proxy Statement is in preliminary form and is subject to
completion. The adoption of the Merger Agreement requires the affirmative vote
of a majority
in number of
shareholders
representing at least 75% in value of the Shares
present and voting together as one class in person or by proxy at the
extraordinary general meeting of shareholders of Tongjitang and entitled to vote
thereon.
The cross
references below are being supplied pursuant to General Instruction G to
Schedule 13E-3 and show the location in the Proxy Statement (or such other
document incorporated herein by reference) of the information required to be
included in response to the items of Schedule 13E-3. Pursuant to
General Instruction F to Schedule 13E-3, the information contained in the Proxy
Statement, including all annexes thereto, is incorporated in its entirety herein
by this reference, and the responses to each Item in this Transaction Statement
are qualified in their entirety by the information contained in the Proxy
Statement and the annexes thereto. Capitalized terms used but not
defined herein shall have the meanings ascribed to such terms in the Proxy
Statement.
All
information contained in this Transaction Statement concerning any of the Filing
Persons has been provided by such Filing Person and no Filing Person has
produced any disclosure with respect to any other Filing Person.
Item
1. Summary of Term Sheet
The information set forth in the Proxy
Statement under the following captions is incorporated herein by
reference:
“Summary Term Sheet”
“Questions and Answers about
the Extraordinary General Meeting and the Merger”
Item
2. Subject Company Information
|
(a)
|
Name and
Address.
The information set forth in the Proxy
Statement under the following caption is incorporated herein by
reference:
|
“Identity
and Background of Filing Persons”
|
(b)
|
Securities
. The
information set forth in the Proxy Statement under the following captions
is incorporated herein by
reference:
|
|
"The
Extraordinary General Meeting—Record Date; Shares Entitled to
Vote"
|
|
“Security
Ownership of Certain Beneficial Owners and Management of
Tongjitang”
|
|
(c)
|
Trading Market and
Price.
The information set forth in the Proxy Statement
under the following caption is incorporated herein by
reference:
|
|
“Market
Price of Tongjitang ADSs, Dividends and other
Matters”
|
|
(d)
|
Dividends
. The
information set forth in the Proxy Statement under the following caption
is incorporated herein by
reference:
|
|
“Market
Price of Tongjitang ADSs, Dividends and Other
Matters”
|
|
(e)
|
Prior Public
Offering
. Not
applicable
|
|
(f)
|
Prior Stock
Purchase
. The information set forth in the Proxy
Statement under the following caption is incorporated herein by
reference:
|
“Transactions
in the Shares and ADSs”
Item
3. Identity and Background of Filing Person
|
(a)-(c)
|
Tongjitang
is the subject company. The information set forth in the Proxy
Statement under the following captions is incorporated herein
by reference:
|
|
“Identity
and Background of Filing Persons”
“Annex D: Directors and Executive Officers
of Fosun, Persons Controlling Fosun and Executive Officers and Directors
of Other Persons in Control of
Fosun”
|
Item
4. Terms of the Transaction
|
(a)
|
Material
Terms
. The information set forth in the Proxy Statement
under the following captions is incorporated herein by
reference:
|
“Special
Factors”
“The
Extraordinary General Meeting”
“The
Merger Agreement”
“Material
U.S. Federal Income Tax Consequences”
“Annex
A—Agreement and Plan of Merger”
|
(c)
|
Different
Terms
. The information set forth in the Proxy Statement
under the following captions is incorporated herein by
reference:
|
“Special
Factors — Interests of Certain Persons in the Merger”
“The
Extraordinary General Meeting—Proposals to Be Considered at the Extraordinary
General Meeting”
“The
Merger Agreement”
“Annex
A—Agreement and Plan of Merger”
|
(d)
|
Appraisal
Rights
. The information set forth in the Proxy Statement
under the following caption is incorporated herein by
reference:
|
“Dissenters’
Rights”
|
(e)
|
Provisions for Unaffiliated
Security Holders
. The information set forth in the Proxy
Statement under the following caption is incorporated herein by
reference:
|
|
“Provisions
for Unaffiliated Security Holders”
|
|
(f)
|
Eligibility of Listing or
Trading
. Not
applicable.
|
Item
5. Past Contacts , Transactions, Negotiations and
Agreements
|
(a)
|
Transactions
. The
information set forth in the Proxy Statement under the following captions
is incorporated herein by
reference:
|
“Special
Factors—Interest of Certain Persons in the Merger”
“Special Factors—Related Party Transactions”
“Transactions
in the Shares and ADSs”
|
(b)
|
Significant Corporate
Events
. The information set forth in the Proxy Statement under the
following captions is incorporated herein by
reference:
|
“Special
Factors—Background of the Proposed Merger”
“Special
Factors—Interest of Certain Persons in the Merger”
“The
Merger Agreement”
“Annex
A—Agreement and Plan of Merger”
|
(c)
|
Negotiations or
Contacts
. The information set forth in the Proxy
Statement under the following captions is incorporated herein by
reference
:
|
“Special
Factors—Background of the Proposed Merger”
“Special
Factors—Interests of Certain Persons in the Merger”
“The
Merger Agreement”
“Annex
A—Agreement and Plan of Merger
|
(e)
|
Agreements Involving the
Subject Company’s Securities
. The information set forth
in the Proxy Statement under the following captions is incorporated herein
by reference:
|
“Special
Factors—Background of the Proposed Merger”
“Special Factors—Plans for Tongjitang after the Proposed
Merger”
“Special
Factors—Voting by Continuing Shareholders at the Extraordinary General
Meeting”
“The
Merger Agreement”
“Transactions
in the Shares and ADSs”
“Annex
A—Agreement and Plan of Merger”
Item
6. Purposes of the Transaction and Plans or Proposals
|
(b)
|
Use of Securities
Acquired
. The information set forth in the Proxy Statement under
the following captions is incorporated herein by
reference:
|
“Special
Factors—Effect of the Proposed Merger on Tongjitang”
“Special
Factors—Purpose of and Reasons for the Proposed Merger”
“The
Merger Agreement”
“Annex
A—Agreement and Plan of Merger”
|
(c)
|
(1)-(8) Plans
. The
information set forth in the Proxy Statement under the following captions
is incorporated herein by
reference:
|
“Special
Factors—Background of the Proposed Merger”
“Special
Factors—Reasons for the Merger and Recommendation of the Independent
Committee and Our Board of Directors”
“Special
Factors—Purpose of and Reasons for the Proposed Merger”
“Special
Factors—Effect of the Proposed Merger on Tongjitang”
“Special
Factors—Plans for Tongjitang After the Proposed Merger”
“Special
Factors—Interests of Certain Persons in the Merger”
“The
Merger Agreement”
“Annex
A—Agreement and Plan of Merger”
Item
7. Purposes, Alternatives, Reasons and Effects
|
(a)
|
Purposes
. The
information set forth in the Proxy Statement under the following captions
is incorporated herein by
reference:
|
“Special
Factors—Reasons for the Merger and Recommendation of the Independent Committee
and Our Board of Directors”
“Special
Factors—Purpose of and Reasons for the Proposed Merger”
|
(b)
|
Alternatives
. The
information set forth in the Proxy Statement under the following captions
is incorporated herein by
reference:
|
“Special
Factors—Background of the Proposed Merger”
“Special
Factors—Reasons for the Merger and Recommendation of the Independent
Committee and Our Board of Directors”
“Special
Factors—Position of the Buyer Parties as to the Fairness of the Proposed
Merger”
“Special
Factors—Purpose of and Reasons for the Proposed Merger”
“Special
Factors—Effects on Tongjitang if the Merger is not Completed”
|
(c)
|
Reasons
. The
information set forth in the Proxy Statement under the following captions
is incorporated herein by
reference:
|
“Special
Factors—Background of the Proposed Merger”
“Special
Factors—Reasons for the Merger and Recommendation of the Independent
Committee and Our Board of Directors”
“Special
Factors—Purpose of and Reasons for the Proposed Merger”
“Special
Factors—Position of the Buyer Parties as to the Fairness of the Proposed
Merger”
“Special
Factors—Effect of the Proposed Merger on Tongjitang”
|
(d)
|
Effects
. The
information set forth in the Proxy Statement under the following captions
is incorporated herein by
reference:
|
“Special
Factors—Background of the Proposed Merger”
“Special
Factors—Reasons for the Merger and Recommendation of the Independent
Committee and Our Board of Directors”
“Special
Factors—Plans for Tongjitang after the Proposed Merger”
“Special
Factors—Effect of the Proposed Merger on Tongjitang”
“Special
Factors—Effect on Tongjitang if the Merger is not Completed”
“Special
Factors—Interests of Certain Persons in the Merger”
“Material
U.S. Federal Income Tax Consequences”
“The
Merger Agreement”
“Annex
A—Agreement and Plan of Merger”
Item
8. Fairness of the Transaction
|
(a)
|
Fairness
. The
information set forth in the Proxy Statement under the following captions
is incorporated herein by
reference:
|
|
“Special
Factors—Background of the Proposed
Merger”
|
“Special
Factors—Reasons for the Merger and Recommendation of the Independent
Committee and Our Board of Directors”
“Special
Factors—Position of the Buyer Parties as to the Fairness of the Proposed
Merger”
“Special
Factors—Opinion of the Independent Committee’s Financial Advisor”
“Special
Factors—Interests of Certain Persons in the Merger”
“Annex
B—Opinion of Morgan Stanley as Financial Advisor”
|
(b)
|
Factors Considered in
Determining Fairness.
The information set forth in the Proxy
Statement under the following captions is incorporated herein by
reference:
|
“Special
Factors—Background of the Proposed Merger”
“Special
Factors—Reasons for the Merger and Recommendation of the Independent
Committee and Our Board of Directors”
“Special
Factors—Position of the Buyer Parties as to the Fairness of the Proposed
Merger”
“Special
Factors—Opinion of the Independent Committee’s Financial Advisor”
“Special
Factors—Interests of Certain Persons in the Merger”
“Annex
B—Opinion of Morgan Stanley as Financial Advisor”
|
(c)
|
Approval of Security
Holders
. The information set forth in the Proxy
Statement under the following caption is incorporated herein by
reference:
|
|
“The
Extraordinary General Meeting—Vote
Required”
|
|
(d)
|
Unaffiliated
Representative
. The information set forth in the Proxy Statement
under the following captions is incorporated herein by
reference:
|
|
“Special
Factors—Background of the Proposed
Merger”
|
|
“Special
Factors—Reasons for the Merger and Recommendation of the Independent
Committee and Our Board of
Directors”
|
|
“Special
Factors—Opinion of the Independent Committee’s Financial
Advisor”.
|
|
(e)
|
Approval of
Directors
. The information set forth in the Proxy
Statement under the following captions is incorporated herein by
reference:
|
|
“Special
Factors—Background of the Proposed
Merger”
|
|
“Special
Factors—Reasons for the Merger and Recommendation of the Independent
Committee and Our Board of
Directors”
|
|
(f)
|
Other
Offers
. The information set forth in the Proxy Statement
under the following captions is incorporated herein by
reference:
|
|
“Special
Factors—Background of the Proposed
Merger”
|
“Special
Factors—Reasons for the Merger and Recommendation of the Independent Committee
and Our Board of Directors”
Item
9. Reports, Opinions, Appraisals and Negotiations
|
(a)
|
Report, Opinion or
Appraisal
. The information set forth in the Proxy Statement under
the following captions is incorporated herein by
reference:
|
“Special
Factors—Background of the Proposed Merger”
“Special
Factors—Opinion of the Independent Committee’s Financial Advisor”
“Annex
B—Opinion of Morgan Stanley as Financial Advisor”
|
(b)
|
Preparer and Summary of the
Report, Opinion or Appraisal
. The information set forth in the
Proxy Statement under the following captions is incorporated herein by
reference:
|
“Special
Factors—Opinion of the Independent Committee’s Financial Advisor”
“Annex
B—Opinion of Morgan Stanley as Financial Advisor”
|
(c)
|
Availability of
Documents
. The information set forth in the Proxy
Statement under the following captions is incorporated herein by
reference:
|
“Special
Factors—Opinion of the Independent Committee’s Financial Advisor”
“Annex
B—Opinion of Morgan Stanley as Financial Advisor”
|
The
reports, opinions or appraisals referenced in this Item 9 will be made
available for inspection and copying at the principal offices of
Tongjitang during its regular business hours by any interested holder of
the Shares or his, her or its representative who has been so designated in
writing.
|
Item
10. Source and Amount of Funds or Other Consideration
|
(a)
|
Source of Funds
. The
information set forth in the Proxy Statement under the following captions
is incorporated herein by
reference:
|
”Special
Factors—Financing”
“The
Merger Agreement”
“Annex
A—Agreement and Plan of Merger”
|
(b)
|
Conditions
. The
information set forth in the Proxy Statement under the following caption
is incorporated herein by
reference:
|
“Special
Factors—Financing”
|
(c)
|
Expenses
. The
information set forth in the Proxy Statement under the following caption
is incorporated herein by
reference:
|
“Special
Factors—Fees and Expenses”
|
(d)
|
Borrowed
Funds
. The information set forth in the Proxy Statement
under the following caption is incorporated herein by
reference:
|
“Special
Factors—Financing”
Item
11. Interest in Securities of the Subject Company
|
(a)
|
Securities Ownership
.
The information set forth in the Proxy Statement under the following
captions is incorporated herein by
reference:
|
“Security
Ownership of Certain Beneficial Owners and Management of
Tongjitang”
“Special
Factors—Interests of Certain Persons in the Merger”
|
(b)
|
Securities Transaction
.
The information set forth in the Proxy Statement under the following
caption is incorporated herein by
reference:
|
“Transactions
in the Shares and ADSs”
Item
12. The Solicitation or Recommendation
|
(d)
|
Intent to Tender or Vote in a
Going Private Transaction
. The information set forth in the
Proxy Statement under the following captions is incorporated herein by
reference:
|
“The
Extraordinary General Meeting—Vote Required”
“Security Ownership of Certain Beneficial Owners and Management of
Tonjitang”
|
(e)
|
Recommendations of
Others
. The information set forth in the Proxy Statement under the
following captions is incorporated herein by
reference:
|
“Special
Factors—Reasons for the Merger and Recommendation of the Independent Committee
and Our Board of Directors”
“Special
Factors—Position of the Buyer Parties as to the Fairness of the Proposed
Merger”
“The
Extraordinary General Meeting—Our Board’s Recommendation”
Item
13. Financial Statements
|
(a)
|
Financial
Information
. The audited financial statements of
Tongjitang for the years ended December 31, 2008 and 2009 are incorporated
herein by reference to Tongjitang’s Form 20-F for the year ended December
31, 2009 filed on June 30, 2010 (see page F-1 and following
pages).
|
|
The
information set forth in the Proxy Statement under the following captions
is incorporated herein by
reference:
|
|
“Where
You Can Find More Information”
|
|
(b)
|
Pro Forma Information
.
Not applicable.
|
Item
14. Persons/Assets, Retained, Employed, Compensated or Used
|
(a)
|
Solicitation or
Recommendations
. The information set forth in the Proxy Statement
under the following caption is incorporated herein by
reference:
|
“The
Extraordinary General Meeting—Solicitation of Proxies”
|
(b)
|
Employees and Corporate
Assets
. The information set forth in the Proxy Statement under the
following captions is incorporated herein by
reference:
|
|
“Directors
and Executive Officers of
Tongjitang”
|
|
“Identity
and Background of Filing Persons”
|
Item
15. Additional Information
|
(b)
|
Other Material
Information
. The information contained in the Proxy Statement,
including all annexes thereto, is incorporated herein by
reference.
|
Item
16. Exhibits
(a)(1)
Proxy Statement of Tongjitang Chinese Medicines Company dated _____________,
2011 (the "Proxy Statement").
(a)(2)
Notice of Extraordinary General Meeting of Shareholders of Tongjitang Chinese
Medicines Company, incorporated herein by reference to the Proxy
Statement.
(a)(3)
Form of Proxy Card, incorporated herein by reference to the Proxy
Statement.
(a)(4)
Press Release dated November 1, 2010 (incorporated by reference to Exhibit 99.1
to the Report on Form 6-K filed by Tongjitang Chinese Medicines Company with the
Securities and Exchange Commission on November 1, 2010).
(a)(5)
Press Release dated November 29, 2010 (incorporated by reference to Exhibit 99.1
to the Report on Form 6-K filed by Tongjitang Chinese Medicines Company with the
Securities and Exchange Commission on November 29, 2010).
(b)(1)
Facility Agreement dated September 24, 2010, by and between Hanmax Investment
Limited and CITIC Bank International Limited (incorporated by reference to
Exhibit 99.10 to Schedule 13D/A of Xiaochun Wang, Hanmax Investment
Limited and Fosun Industrial Co., Limited with respect to Tongjitang Chinese
Medicines Company, filed on October 12, 2010).
(c)(1)
Opinion of Morgan Stanley, dated October 29, 2010, incorporated herein by
reference to Annex B of the Proxy Statement , which Morgan Stanley has
consented to be filed herewith .
(c)(2)
Discussion Materials prepared by Morgan Stanley for discussion with the
independent committee of the board of directors of the Company, dated October
12, 2010 , which Morgan Stanley has consented to be filed
herewith . *
(c)(3)
Discussion Materials prepared by Morgan Stanley for discussion with the
independent committee of the board of directors of the Company, dated October
29, 2010 , which Morgan Stanley has consented to be filed
herewith . *
(d)(1)
Agreement and Plan of Merger dated as of October 29, 2010, by and among
Tongjitang Chinese Medicines Company, Fosun Industrial Co., Limited, Hanmax
Investment Limited and Tonsun International Company Limited, incorporated herein
by reference to Annex A to the Proxy Statement.
(f)(1)
Dissenters’ Rights, incorporated herein by reference to the Section entitled
"Dissenters’ Rights" in the Proxy Statement.
(f)(2)
Section 238 of the Cayman Islands Companies Law (2010 Revision),
incorporated herein by reference to Annex C of the Proxy Statement.
(g) Not
applicable.
|
Previously filed with the
Securities and Exchange Commission as an exhibit to the Transaction
Statement on November 26,
2010.
|
SIGNATURES
After reasonable inquiry and to the
best of my knowledge and belief, I certify that the information set forth in
this statement is true, complete and correct.
Date:
January 19, 2011
TONGJITANG
CHINESE MEDICINES COMPANY
|
|
By:
|
/s/
Justin Yan Chen
|
|
Name:
Justin Yan Chen
|
|
Title:
Chief Operating Officer and Director
|
|
|
HANMAX
INVESTMENT LIMITED
|
|
By:
|
/s/
Xiaochun Wang
|
|
Name:
Xiaochun Wang
|
|
Title:
Director
|
|
|
FOSUN
INDUSTRIAL CO., LIMITED
|
|
By:
|
/s/
Qiyu Chen
|
|
Name:
Qiyu Chen
|
|
Title:
Chairman of Board of Directors
|
|
|
TONSUN
INTERNATIONAL COMPANY LIMITED
|
|
By:
|
/s/
Xiaochun Wang
|
|
Name:
Xiaochun Wang
|
|
Title:
Director
|
MR.
XIAOCHUN WANG
|
|
|
By:
|
/s/ Xiaochun
Wang
|
SHANGHAI
FOSUN PHARMACEUTICAL (GROUP) CO. LTD.
|
|
By:
|
/s/ Qiyu Chen
|
|
Name:
Qiyu Chen
|
|
Title:
Chairman of the Board of
Directors
|
FOSUN
HIGH TECHNOLOGY (GROUP) CO. LTD.
|
|
By:
|
/s/ Guangchang
Guo
|
|
Name:
Guangchang Guo
|
|
Title:
Chairman of the Board of
Directors
|
FOSUN
INTERNATIONAL LIMITED
|
|
|
By:
|
/s/ Guangchang
Guo
|
|
Name:
Guangchang Guo
|
|
Title:
Chairman of the Board of
Directors
|
|
|
|
|
By:
|
|
|
Name:
Guangchang Guo
|
|
Title:
Director
|
|
|
FOSUN
INTERNATIONAL HOLDINGS LTD.
|
|
|
By:
|
|
|
Name:
Guangchang Guo
|
|
Title:
Director
|
|
|
|
|
|
By:
|
|
Exhibit
Index
(a)(1)
Proxy Statement of Tongjitang Chinese Medicines Company dated _____________,
2011 (the "Proxy Statement").
(a)(2)
Notice of Extraordinary General Meeting of Shareholders of Tongjitang Chinese
Medicines Company, incorporated herein by reference to the Proxy
Statement.
(a)(3)
Form of Proxy Card, incorporated herein by reference to the Proxy
Statement.
(a)(4)
Press Release dated November 1, 2010 (incorporated by reference to Exhibit 99.1
to the Report on Form 6-K filed by Tongjitang Chinese Medicines Company with the
Securities and Exchange Commission on November 1, 2010).
(a)(5)
Press Release dated November 29, 2010 (incorporated by reference to Exhibit 99.1
to the Report on Form 6-K filed by Tongjitang Chinese Medicines Company with the
Securities and Exchange Commission on November 29, 2010).
(b)(1)
Facility Agreement dated September 24, 2010, by and between Hanmax Investment
Limited and CITIC Bank International Limited (incorporated by reference to
Exhibit 99.10 to Schedule 13D/A of Xiaochun Wang, Hanmax Investment
Limited and Fosun Industrial Co., Limited with respect to Tongjitang Chinese
Medicines Company, filed on October 12, 2010).
(c)(1)
Opinion of Morgan Stanley, dated October 29, 2010, incorporated herein by
reference to Annex B of the Proxy Statement.
(c)(2)
Discussion Materials prepared by Morgan Stanley for discussion with the
independent committee of the board of directors of the Company, dated October
12, 2010 , which Morgan Stanley has consented to be filed
herewith . *
(c)(3)
Discussion Materials prepared by Morgan Stanley for discussion with the
independent committee of the board of directors of the Company, dated October
29, 2010 , which Morgan Stanley has consented to be filed
herewith . *
(d)(1)
Agreement and Plan of Merger dated as of October 29, 2010, by and among
Tongjitang Chinese Medicines Company, Fosun Industrial Co., Limited, Hanmax
Investment Limited and Tonsun International Company Limited, incorporated herein
by reference to Annex A to the Proxy Statement.
(f)(1)
Dissenters’ Rights, incorporated herein by reference to the Section entitled
"Dissenters’ Rights" in the Proxy Statement.
(f)(2)
Section 238 of the Cayman Islands Companies Law (2010 Revision), incorporated
herein by reference to Annex C of the Proxy Statement.
(g) Not
applicable.
*
|
Previously filed with the
Securities and Exchange Commission as an exhibit to this Transaction
Statement on November 26, 2010.
|
Tycom Ltd (NYSE:TCM)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tycom Ltd (NYSE:TCM)
Historical Stock Chart
From Oct 2023 to Oct 2024